“…This trend is not significant because of the small numbers in each group, further study with larger numbers of patients was necessary to confirm the role of initial BMI in diabetes remission. Our remission results were similar to those reported by Huang et al [14] in patients with BMI 25-35 kg/m 2 , but higher than those reported by Malapan et al [7] in non-obese T2D patients. Such discrepancies show the importance of appropriate patient selection in low-BMI T2D patients.…”
Section: Discussionsupporting
confidence: 91%
“…The surgical indications are based on BMI and several studies have reported positive surgical outcomes in patients with non-obese BMIs, supporting the efficacy of RYGB in overweight patients or even those with normal BMI [6,7]. Huang and colleagues demonstrated that RYGB was well tolerated and feasible with good T2D remission rates in patients with BMI ranging from 25 to 35 kg/m 2 [14].…”
Section: Discussionmentioning
confidence: 97%
“…Lee and colleagues showed that elevated BMI could be a predictor of remission following bariatric surgery in T2D patients [5]. However, several other studies support RYGB's efficacy in low-or even normal-BMI patients [6,7]. Research shows that the most probable mechanism for the antidiabetic effects of bariatric Hongwei Zhang and Xiaodong Han contributed equally to this work.…”
RYGB effectively treated T2D patients in our study, even in low-BMI patients, and resulted in diabetes remission and metabolic disorder control, reducing cardiovascular risk.
“…This trend is not significant because of the small numbers in each group, further study with larger numbers of patients was necessary to confirm the role of initial BMI in diabetes remission. Our remission results were similar to those reported by Huang et al [14] in patients with BMI 25-35 kg/m 2 , but higher than those reported by Malapan et al [7] in non-obese T2D patients. Such discrepancies show the importance of appropriate patient selection in low-BMI T2D patients.…”
Section: Discussionsupporting
confidence: 91%
“…The surgical indications are based on BMI and several studies have reported positive surgical outcomes in patients with non-obese BMIs, supporting the efficacy of RYGB in overweight patients or even those with normal BMI [6,7]. Huang and colleagues demonstrated that RYGB was well tolerated and feasible with good T2D remission rates in patients with BMI ranging from 25 to 35 kg/m 2 [14].…”
Section: Discussionmentioning
confidence: 97%
“…Lee and colleagues showed that elevated BMI could be a predictor of remission following bariatric surgery in T2D patients [5]. However, several other studies support RYGB's efficacy in low-or even normal-BMI patients [6,7]. Research shows that the most probable mechanism for the antidiabetic effects of bariatric Hongwei Zhang and Xiaodong Han contributed equally to this work.…”
RYGB effectively treated T2D patients in our study, even in low-BMI patients, and resulted in diabetes remission and metabolic disorder control, reducing cardiovascular risk.
“…Unfortunately, there is little evidence-based information on the effectiveness of bariatric surgery in diabetic patients with BMI Z30 and o35 kg/m 2 , and in this subgroup of patients, indication for bariatric surgery should be individually assessed [29]. Recently, a favorable metabolic response to gastric bypass has also been reported in nonobese diabetic Asian patients [30], though further studies are required to confirm these promising findings.…”
“…Furthermore, the outcomes of bariatric surgery in a series of 29 Asian patients with a BMI < 27 kg/m 2 are most convincing. In that series, Malapan et al (5) concluded that ''all clinical and biochemical parameters, except uric acid, were significantly improved.'' Diabetes mellitus remission was achieved in 11 patients (37.9%).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.